Last reviewed · How we verify
Xingnaojing injection
Xingnaojing injection is a traditional Chinese medicine formulation that enhances cerebral blood flow and protects neural tissue through multiple bioactive components.
Xingnaojing injection is a traditional Chinese medicine formulation that enhances cerebral blood flow and protects neural tissue through multiple bioactive components. Used for Acute ischemic stroke, Cerebral infarction, Post-stroke recovery and rehabilitation.
At a glance
| Generic name | Xingnaojing injection |
|---|---|
| Sponsor | Dongzhimen Hospital, Beijing |
| Drug class | Traditional Chinese medicine injection |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
The injection contains active compounds derived from traditional Chinese herbs that work synergistically to improve microcirculation in the brain, reduce inflammation, and provide neuroprotective effects. It is believed to enhance cerebral metabolism and oxygen utilization while reducing ischemic damage in acute stroke and related cerebrovascular conditions.
Approved indications
- Acute ischemic stroke
- Cerebral infarction
- Post-stroke recovery and rehabilitation
Common side effects
- Injection site reactions
- Allergic reactions
- Dizziness
- Headache
Key clinical trials
- The Study on the Efficacy of tDCS Stimulation of the Cerebellum Combined With XingNaoJing Injection in Patients With Consciousness Disorders After Cranial Injury (PHASE4)
- Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke (PHASE4)
- Analysing the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke (NA)
- Clinical Evaluation of the Combination of Symptoms and Symptoms With General Treatment for Acute Hemorrhagic Stroke (PHASE4)
- Xingnaojing for Mild-to-severe Acute Ischemic Stroke (PHASE4)
- Trial of pRehospital Intervention With trAditional Chinese Medicine for Acute strokE
- Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS) (PHASE4)
- Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xingnaojing injection CI brief — competitive landscape report
- Xingnaojing injection updates RSS · CI watch RSS
- Dongzhimen Hospital, Beijing portfolio CI